___

• 1. Revill P, Serradell N, Bolos J. Paliperidone: antipsychotic agent treatment of bipolar disorder dual dopamine D2/5- HT2A receptor antagonist. Drugs Future. 2006;31:579-84.
• 2. Meltzer HY, Bobo WV, Nuamah IF, Lane R, Hough D, Kramer M, Eerdekens M. Efficacy and tolerability of oral paliperidone extended-release tablets in the treatment of acute schizophrenia: pooled data from three 6-week, placebo-controlled studies. J Clin Psychiatry. 2008;69:817-29.
• 3. Gopal S, Vijapurkar U, Lim P, Morozova M, Eerdekens M, Hough D. 52-week open-label study of the safety and tolerability of paliperidone palmitate in patients with schizophrenia. J Psychopharmacol. 2011;25:685-97.
• 4. Gopal S, Xu H, Bossie C, Burón JA, Fu DJ, Savitz A, Nuamah I, Hough D. Incidence of tardive dyskinesia: a comparison of longacting injectable and oral paliperidone clinical trial databases.Int J Clin Pract. 2014;68:1514-22.
• 5. Owens DGC. Tardive dyskinesia. A guide to the extrapyramidal side effects of antipsychotic drugs. Cambridge, UK: Cambridge University Press, 1999; s. 166-226.
• 6. Osorio RS, Agüera-Ortiz L, Hurtado de Mendoza A, Ramos I, Palomo T. Treatment of Tardive Dyskinesia with Aripiprazole. Neurotox Res. 2010;17:432-4.